Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.

Détails

ID Serval
serval:BIB_24965
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.
Périodique
Clinical and Experimental Hypertension
Auteur(s)
Bogousslavsky J., Paciaroni M., Gallai V.
ISSN
1064-1963 (Print)
ISSN-L
1064-1963
Statut éditorial
Publié
Date de publication
2002
Volume
24
Numéro
7-8
Pages
603-610
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.
Mots-clé
Brain Ischemia/drug therapy, Fibrinolytic Agents/therapeutic use, Humans, North America, Platelet Activation/drug effects, Platelet Aggregation Inhibitors/therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex/therapeutic use, Randomized Controlled Trials as Topic, Stroke/drug therapy, Tissue Plasminogen Activator/therapeutic use, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/11/2007 13:21
Dernière modification de la notice
20/08/2019 14:02
Données d'usage